BIOMAT Database Logo BIOMAT Database Logo

Endothelial cell destruction by polymorphonuclear leukocytes incubated with sera from patients with systemic lupus erythematosus (SLE). 1992

Y Hashimoto, and K Nakano, and S Yoshinoya, and K Tanimoto, and K Itoh
Department of Internal Medicine & Physical Therapy, University of Tokyo School of Medicine, Japan.

When normal polymorphonuclear leukocytes (PMN) were incubated with sera from patients with active systemic lupus erythematosus (SLE), a significantly increased cytotoxicity against human cultured vascular endothelial cells (EC), compared with normal control sera, was demonstrated by the standard 51Cr release method. The degree of this cytotoxicity was correlated with the immune complex level in each serum. The cytotoxicity did not correlate with the presence of anti-EC antibody. An absorption study with C1q-Sepharose 4B further suggested that the immune complexes are the factor which induce cytotoxicity. A gel fractionation study, however, indicated the heterogenity of the cytotoxic activity, and suggested the possible contribution of other substances including anti-EC, at least in some of the patients. This type of cytotoxicity may initiate the inflammatory process including vascular damage of the disease.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D002458 Cell Fractionation Techniques to partition various components of the cell into SUBCELLULAR FRACTIONS. Cell Fractionations,Fractionation, Cell,Fractionations, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002850 Chromatography, Gel Chromatography on non-ionic gels without regard to the mechanism of solute discrimination. Chromatography, Exclusion,Chromatography, Gel Permeation,Chromatography, Molecular Sieve,Gel Filtration,Gel Filtration Chromatography,Chromatography, Size Exclusion,Exclusion Chromatography,Gel Chromatography,Gel Permeation Chromatography,Molecular Sieve Chromatography,Chromatography, Gel Filtration,Exclusion Chromatography, Size,Filtration Chromatography, Gel,Filtration, Gel,Sieve Chromatography, Molecular,Size Exclusion Chromatography
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D005260 Female Females

Related Publications

Y Hashimoto, and K Nakano, and S Yoshinoya, and K Tanimoto, and K Itoh
Enhanced glucose oxidation by leukocytes incubated with sera from patients with rheumatoid arthritis and systemic lupus erythematosus (SLE).
December 1971, The Journal of laboratory and clinical medicine,
Y Hashimoto, and K Nakano, and S Yoshinoya, and K Tanimoto, and K Itoh
Chemotaxis of polymorphonuclear leukocytes from patients with systemic lupus erythematosus and Felty's syndrome.
January 1972, Immunological communications,
Y Hashimoto, and K Nakano, and S Yoshinoya, and K Tanimoto, and K Itoh
Sera from patients with systemic lupus erythematosus reactive with human endothelial cells.
January 1981, The Journal of rheumatology,
Y Hashimoto, and K Nakano, and S Yoshinoya, and K Tanimoto, and K Itoh
['Delayed' cutaneous hypersensitivity to leukocytes in patients with systemic lupus erythematosus (SLE)].
December 1962, Archives of interamerican rheumatology : A.I.R,
Y Hashimoto, and K Nakano, and S Yoshinoya, and K Tanimoto, and K Itoh
Increased superoxide production by polymorphonuclear leukocytes in systemic lupus erythematosus.
January 1991, Clinical and experimental rheumatology,
Y Hashimoto, and K Nakano, and S Yoshinoya, and K Tanimoto, and K Itoh
C3b receptor (CR1) expression on the polymorphonuclear leukocytes from patients with systemic lupus erythematosus.
February 1987, Clinical and experimental immunology,
Y Hashimoto, and K Nakano, and S Yoshinoya, and K Tanimoto, and K Itoh
Differential generation of chemiluminescence--detectable oxygen radicals by normal polymorphonuclear leukocytes challenged with sera from systemic lupus erythematosus and rheumatoid arthritis patients.
August 1984, Klinische Wochenschrift,
Y Hashimoto, and K Nakano, and S Yoshinoya, and K Tanimoto, and K Itoh
Decreased IL-12 production by polymorphonuclear leukocytes in patients with active systemic lupus erythematosus.
January 2002, Immunological investigations,
Y Hashimoto, and K Nakano, and S Yoshinoya, and K Tanimoto, and K Itoh
Induction of lupus inclusions by sera from patients with systemic lupus erythematosus.
April 1986, Arthritis and rheumatism,
Y Hashimoto, and K Nakano, and S Yoshinoya, and K Tanimoto, and K Itoh
Increased endothelial cell adherence, aggregation, and superoxide generation by neutrophils incubated in systemic lupus erythematosus and Felty's syndrome sera.
December 1982, Arthritis and rheumatism,
Copied contents to your clipboard!